Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement; [Prophylaxe mit langwirksamen Granulozyten-Kolonie-stimulierenden Faktoren (G-CSF) bei gynäkologischen Malignomen]

被引：4

作者：

Petru E. ^{[1
]}

Singer C.F. ^{[2
]}

Polterauer S. ^{[2
]}

Galid A. ^{[3
]}

Schauer C. ^{[4
]}

Klocker J. ^{[5
]}

Seifert M. ^{[2
]}

Reinthaller A. ^{[2
]}

Benedicic C. ^{[1
]}

Hubalek M. ^{[6
]}

Hefler L. ^{[7
]}

Marth C. ^{[6
]}

Scholl-Firon T. ^{[8
]}

Bogner G. ^{[9
]}

Zeimet A.-G. ^{[6
]}

机构：

[1] Division of Gynecology, Department of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, Graz

[2] Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna

[3] Department of Obstetrics and Gynecology, Hanuschkrankenhaus, Vienna

[4] Department of Gynecology, Hospital Barmherzige Brüder Graz, Graz

[5] Department of Internal Medicine, Klinikum Klagenfurt, Klagenfurt

[6] Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck

[7] Department of Gynecology, Hospital Barmherzige Schwestern, Linz

[8] Department of Obstetrics and Gynecology, Wilhelminenspital, Vienna

[9] Department of Obstetrics and Gynecology, Paracelsus University of Salzburg, Salzburg

来源：

Wiener Medizinische Wochenschrift | 2015年 / 165卷 / 19-20期

关键词：

Chemotherapy-induced neutropenia; Febrile neutropenia; Granulocyte colony-stimulating factors (G-CSF); Gynecologic cancer; Long-acting granulocyte colony stimulating factors;

D O I：

10.1007/s10354-015-0392-3

中图分类号：

学科分类号：

摘要：

We reviewed the status of the use of the prophylactic long-acting granulocyte colony-stimulating factors (G-CSFs) pegfilgrastim and lipegfilgrastim in gynecologic malignancies. Long-acting G-CSFs should not be used in weekly regimens. Filgrastim is not indicated in patients with febrile and/or severe neutropenia after administration of long-acting G-CSF in the same cycle. One study has shown a moderate effect on febrile neutropenia of ciprofloxacin when co-administered with pegfilgrastim. There is broad evidence from meta-analyses that pegfilgrastim effectively reduces severe neutropenia. In parallel, its adverse effects have been studied extensively. All-cause mortality was significantly reduced by pegfilgrastim. The glycopegylated long-acting G-CSF, lipegfilgrastim has demonstrated antineutropenic efficacy similar to that of pegfilgrastimin in one breast cancer study. In another pivitol non-small cell lung cancer study, impaired survival was observed in the lipegfilgrastim group during the first 30 days of study. The European Medicines Agency claimed more profound safety data to be provided for lipegfilgrastim by 2017. © 2015, Springer-Verlag Wien.

引用

页码：387 / 394

页数：7

共 52 条

[1]

Aapro M.S., Bohlius J., Cameron D., Dal Lago L., Donnelly J.P., Kearney N., Lyman G.H., Pettengell R., Tjan-Heijnen V.C., Walewski J., Weber D.C., Zielinski C., 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, Eur J Cancer, 47, pp. 8-32, (2011)

[2]

Crawford J., Caserta C., Roila F., Haematopoietic growth factors: ESMO clinical practice guidelines for the applications, Ann Oncol, 21, 5, pp. 246-251, (2010)

[3]

Von Minckwitz G., Kummel S., DuBois A., Eiermann W., Eidtmann H., Gerber B., Hilfrich J., Huober J., Costa S.D., Jackisch C., Grasshoff S.T., Vescia S., Skacel T., Loibl S., Mehta K.M., Kaufmann M., Pegfilgrastim +/− ciprofloxacin for primary prophylaxis with TAC docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study, Ann Oncol, 19, pp. 292-298, (2008)

[4]

Alba E., Martin M., Ramos M., Adrover E., Balil A., Jara C., Barnadas A., Fernandez-Aramburo A., Sanchez-Rovira P., Amenedo M., Casado A., Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study, J Clin Oncol, 22, 13, pp. 2587-2593, (2004)

[5]

Clark O.A., Lyman G.H., Castro A.A., Clark L.G., Djulbegovic B., Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials, J Clin Oncol, 23, pp. 4198-4212, (2005)

[6]

Timmer-Bonte J., Adang E., Smit H., Biesma B., Wilschut F.A., Bootsma G.P., de Boo T.M., Tjan-Heijnen V.C., Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer, J Clin Oncol, 24, 19, pp. 2991-2997, (2006)

[7]

De Naurois J., Novitzky-Basso I., Gill M., Marti Marti F., Cullen M., Rolla F., Management of febrile neutropenia: ESMO clinical practice guidelines, Ann Oncol, 21, 5, pp. 252-256, (2010)

[8]

Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Somerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J., Wolff A.C., 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, 24, pp. 3187-3205, (2006)

[9]

Myeloid growth factors, Version, (2014)

[10]

Crawford J., Allen J., Armitage J., Balducci L., Becker P., Blayney D., Cataland S., Heaney M., Hudock S., Kloth D., Kuter D., Lyman G., McMahon B., Myeloid Growth Factors, JNCCN, 9, pp. 1266-1290, (2011)

← 1 2 3 4 5 6 →